Latest News and Press Releases

CAMBRIDGE, Mass., Sept. 24, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...

CAMBRIDGE, Mass., Sept. 24, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to...

CAMBRIDGE, Mass., Sept. 9, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...

CAMBRIDGE, Mass., Sept. 3, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...

CAMBRIDGE, Mass., Aug. 27, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) today announced that it has received a closeout letter from the Office of Prescription Drug Promotion...

CAMBRIDGE, Mass., Aug. 12, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) today announced the pricing of its offering of $300 million aggregate principal amount of 2.00%...

CAMBRIDGE, Mass., Aug. 11, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) today announced its intention to offer, subject to market and other customary conditions, $250 million...

CAMBRIDGE, Mass., Aug. 8, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...

CAMBRIDGE, Mass., July 30, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...

-  Company achieves $36.0 million in net product sales of JUXTAPID® with 34% growth in sales over first quarter -   Cash flow positive operations anticipated in the second...